Optimizing the Temperature for Embryo Culture in In Vitro Fertilization

Optimizing the Temperature for Embryo Culture in In Vitro Fertilization: A Randomized Controlled Trial

Many human and animal studies over the past 40 years have revealed that ovaries and Fallopian tubes have a lower temperature than core body temperature, especially around the time of ovulation and early embryo development. Whether average core body temperature, 37 degrees Celsius, is ideal temperature for culture has not been prospectively evaluated. The purpose of this study is to determine whether lowering the incubator temperature by 1 degree Celsius will result in meaningful improvements in embryo development and pregnancy rates.

Patients participating in this study will undergo routine in vitro fertilization (IVF) stimulation. Following egg retrieval, patients with at least 8 mature eggs will have those eggs divided randomly into two groups. Both groups will then under ICSI (intra-cytoplasmic sperm injection) to fertilize the eggs. The groups will randomly be assigned to control or study condition. The control condition group will be cultured at 37 degrees Celsius, the current standard of care. The study group will be cultured at 36 degrees Celsius. All other culture conditions will be kept identical and embryos will be assessed on day 3 and day 5 of development.

On day 5, all well-developed blastocysts will undergo biopsy for Comprehensive Chromosomal Screening (CCS), which will evaluate the chromosomal normalcy of the embryo . Patients will undergo transfer on the morning of day 6 and the highest quality, chromosomally normal embryo from each group (the 36 degree cultured embryos and the 37 degree cultured embryos) will be transferred. If only 1 embryo is available for transfer, the patient will have a single embryo transfer.

All embryos available for cryopreservation will undergo biopsy for CCS before being frozen. Some arrested embryos from each temperature group will also undergo genetic analysis to evaluate chromosomal normalcy or mosaicism.

The female patient will undergo a blood draw at 9 weeks gestation and buccal swabs will be obtained from the infant(s) after birth.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

55

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New Jersey
      • Morristown, New Jersey, United States, 07960
        • Reproductive Medicine Associates of new Jersey
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18104
        • Reproductive Medicine Associates of Pennsylvannia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 41 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • No more than 1 prior failed cycle at RMA NJ facility; up to 2 prior failed cycles at another facility pending investigator review
  • Female partner between 18 and 41 at onset of IVF cycle
  • Normal day 3 FSH (< or = 12) in RMA NJ laboratory
  • Basal antral follicle count of at least 10
  • Male partner with greater than 100,000 total motile spermatozoa per ejaculate (donor sperm is ok)
  • BMI < or = 32 kg/m2

Exclusion Criteria:

  • Diagnosis of chronic anovulation (cycles occuring typically less often than every 90 days)
  • Use of testicular aspiration or biopsy procedures to obtain sperm
  • Unevaluated ovarian mass or diagnosis of surgically-confirmed stage IV endometriosis
  • Presence of hydrosalpinges that communicate with the uterine cavity
  • History of endometrial insufficiency
  • Any contraindication to undergoing IVF or gonadotropin stimulation
  • Prior poor fertilization rate- less than 50% of mature eggs
  • Prior poor blastulation rate- less than 10% of 2PNs (day 1 embryos)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 36 degree group
36 degrees Celsius for the incubators is the experimental condition in this study.
Embryos in this group will be cultured in incubators set to 36 degrees Celsius.
Other Names:
  • IVF, PGD, embryos, culture, CCS, infertility
No Intervention: 37 degree group
37 degrees Celsius is the standard incubator temperature for the culture of embryos.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Useable Blastocyst Formation Rate
Time Frame: approximately 1 week
Proportion of mature eggs developing into expanded blastocysts (Gardner grade 3-6) of sufficient quality to transfer or cryopreserve will be documented for each group (36 degree and 37 degree group).
approximately 1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fertilization rate
Time Frame: approximately 2 days
The proportion of mature eggs that underwent ICSI and are normally fertlized (documented as forming 2 pro-nuclei (2PNs)) on the day after egg retrieval will be documented for each group (36 degree and 37 degree groups)
approximately 2 days
Cleavage Rate
Time Frame: approximately 1 week
Proportion of properly fertlized embryo (2PNs on day 1) that undergo further celluar division will be documented for each group (36 degree and 37 degree group).
approximately 1 week
Blastocyst Formation Rate
Time Frame: approximately 1 week
Proportion of mature oocytes that go on to develop into blastocysts in each group (36 degree group and 37 degree group) will be documented.
approximately 1 week
Implantation Rate
Time Frame: approximately 2 weeks
Proportion of transferred embryos resulting in a clinically documented pregnancy will be documented for each group (36 degree and 37 degree group).
approximately 2 weeks
Aneuploidy Rate
Time Frame: approximately 1 month
Rate of chromosomal abnormalities among the embryos in each group (36 degree and 37 degree groups) as determined by polymerase chain reaction (PCR) based comprehensive chromosome screening (CCS).
approximately 1 month
Mosaicism Rate
Time Frame: approximately 1 month
Proportion of embryos that arrest at the cleavage stage which show evidence of more than one chromosomal lineages (mosaicism) when analyzed my microarray documented in each group (36 degree and 37 degree group).
approximately 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Richard T Scott, MD, Reproductive Medicine Associates of new Jersey

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2012

Primary Completion (Actual)

January 1, 2014

Study Completion (Actual)

July 1, 2014

Study Registration Dates

First Submitted

January 3, 2012

First Submitted That Met QC Criteria

January 6, 2012

First Posted (Estimate)

January 9, 2012

Study Record Updates

Last Update Posted (Estimate)

March 26, 2015

Last Update Submitted That Met QC Criteria

March 25, 2015

Last Verified

March 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RMA-2011-02

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infertility

Clinical Trials on 36 degrees Celsius

Subscribe